Chia‐Chi Lin

8.9k citations

62 papers · 3.5k indexed · 4 hit papers · h-index 25

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes

Papers in

Oncology 35
- Cancer Immunotherapy and Biomarkers 11
- Colorectal Cancer Treatments and Studies 10
- Lung Cancer Research Studies 10
- Pancreatic and Hepatic Oncology Research 4
Pulmonary and Respiratory Medicine 23
- Lung Cancer Treatments and Mutations 14

Co-authors: Ravit Geva Hyun Cheol Chung Shilpa Gupta Joseph P. Eder Kumudu Pathiraja Barbara Burtness Kei Muro Yung‐Jue Bang
Journals: Journal of Clinical Oncology (5 papers)Clinical Cancer Research (4 papers)Journal of Thoracic Oncology (4 papers)European Journal of Cancer (4 papers)Annals of Oncology (3 papers)
Partner nations: Taiwan United States South Korea

In The Last Decade

Chia‐Chi Lin

61 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors 2021 · 257 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Clinical Cancer Research
2021 The Lancet Oncology
2018 British Journal of Cancer
2016 The Lancet Oncology

Peers

Countries citing papers authored by Chia‐Chi Lin

Since Specialization

Citations

This map shows the geographic impact of Chia‐Chi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia‐Chi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia‐Chi Lin more than expected).

Fields of papers citing papers by Chia‐Chi Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chia‐Chi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia‐Chi Lin. The network helps show where Chia‐Chi Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Chia‐Chi Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chia‐Chi Lin Line = papers co-authored together Chia‐Chi Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study BMJ Open ·Chia‐Chi Lin, Giuseppe Curigliano, Armando Santoro, Dong‐Wan Kim, David Tai, F. Stephen Hodi, Sofie Wilgenhof, Toshihiko Doi, Catherine Sabatos-Peyton, Sebastian Szpakowski, Shripad Chitnis, Alexandros Xyrafas, Sabine Gutzwiller, Alessandro Pastore, Nicolas Mach	2024	8
2	A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer British Journal of Cancer ·Valentine M. Macaulay, Simon Lord, Syed A. Hussain, Pablo Maroto, Robert H. Jones, Miguel Ángel Climent, Natalie Cook, Chia‐Chi Lin, Shian‐Shiang Wang, Diletta Bianchini, Mark Bailey, M. Wang, Thomas Bogenrieder, Johann S. de Bono	2023	3
3	Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study Cancer ·Do‐Youn Oh, Alain P. Algazi, Jaume Capdevila, Federico Longo, Wilson H. Miller, Francesca Sovran, Carlos Bonilla, Hyun Cheol Chung, Tormod Kyrre Guren, Chia‐Chi Lin, Daniel Motola‐Kuba, Manisha H. Shah, Julien Hadoux, Sarah Al-Alwan, Fan Jin, Kevin Norwood, Loïc Lebellec	2023	31
4	Immunotherapy in anaplastic thyroid cancer: Case series Journal of the Formosan Medical Association ·Shyang‐Rong Shih, S H Lee, Kuan‐Yu Lin, Pan‐Chyr Yang, Kuan-Yuan Chen, Chunwei Wang, Chun‐Nan Chen, Chih‐Feng Lin, Chia‐Chi Lin, (unknown), (unknown)	2022	11
5	Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors Clinical Cancer Research ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing Hit paper breakdown →	2021	257
6	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Rafał Dziadziuszko, Matthew Krebs, Filippo de Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish Patel, Byoung Chul Cho, Stephen V. Liu, Myung‐Ju Ahn, Chao‐Hua Chiu, Anna F. Farago, Chia‐Chi Lin, Christos S. Karapetis, Yu Li, Bann‐Mo Day, David Chen, Timothy R. Wilson, Fabrice Barlési	2021	111
7	Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study Clinical Cancer Research ·Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suárez, Chia‐Chi Lin, Richard Quek, Marie Luise Hütter‐Krönke, Ricardo Cubedo, Stéphane Ferretti, Nelson Guerreiro, Astrid Jullion, Elena J. Orlando, César Estébanez Tascón, Janna Dejmek, Ensar Halilovic, Claire Fabre, Jean‐Yves Blay, Antoîne Italiano	2021	43
8	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Targeted Oncology ·Toshio Shimizu, Yasutoshi Kuboki, Chia‐Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, Grant Grove, Neeraj Gupta, Farhad Sedarati, Kyu‐pyo Kim	2021	5
9	Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Oncology ·Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Jolanta Krajewska, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer Oliver, Bhumsuk Keam, Jaume Capdevila Hit paper breakdown →	2021	156
10	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial Clinical Cancer Research ·Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung‐Jue Bang, Chia‐Chi Lin, Wu‐Chou Su, Antoîne Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, DM Rearden, Lian-li Zhang, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna C. Bendell	2020	31
11	Quinoidal thioalkyl-substituted bithiophene small molecule semiconductors for n-type organic field effect transistors Journal of Materials Chemistry C ·P de Rijke, Evangelos Kanoulas, Chia‐Chi Lin, A J Palmer, Christian Castro, sonia ijaz, Tatiana Borisovna Putivskaia, Arulmozhi Velusamy, 李莉, Gene‐Hsiang Lee, Shueh-Lin Yau, Shih‐Huang Tung, Takeo Minari, Cheng‐Liang Liu, Ming‐Chou Chen	2020	11
12	Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) European Journal of Cancer ·Yung‐Jue Bang, Talia Golan, Laëtitia Dahan, Siqing Fu, Víctor Moreno, Keunchil Park, Ravit Geva, Filippo de Braud, Zev A. Wainberg, Martin Reck, Laura W. Goff, Naomi Laing, Gu Mi, Joana Oliveira, Carlos Fabian Rodríguez Alvis, Chia‐Chi Lin	2020	103
13	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma European Journal of Cancer ·Lu Si, Xiaoshi Zhang, Sang Joon Shin, Yun Fan, Chia‐Chi Lin, Tae Min Kim, Arunee Dechaphunkul, Delvia Roza, Lucette BARDET, Palanichamy Ilankumaran, Yong Sang Lee, Eduard Gasal, Haifu Li, Jun Guo	2020	12
14	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC Journal of Thoracic Oncology ·Viola W. Zhu, 義忠森, Dong‐Wan Kim, Herbert H. Loong, Misako Nagasaka, Febby Fajar Nugraha, Yvonne Ang, Chan-Young Ock, Nishan Tchekmedyian, Sai‐Hong Ignatius Ou, Nicholas Syn, Thanyanan Reungwetwattana, Chia‐Chi Lin, Ross A. Soo	2020	51
15	Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer BMC Cancer ·Janice M. Mehnert, Andréa Varga, Marcia S. Brose, Rahul Aggarwal, Chia‐Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha‐Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam	2019	148
16	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial The Lancet Oncology ·Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Talia Golan, Dung T. Le, Barbara Burtness, Autumn J. McRee, Chia‐Chi Lin, Kumudu Pathiraja, Jared Lunceford, Kenneth Emancipator, Jonathan Juco, Minori Koshiji, Yung‐Jue Bang Hit paper breakdown →	2016	848
17	479TiP Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC) Annals of Oncology ·Daniel S.W. Tan, Chia‐Chi Lin, Takahiro Fukube, Se-Gwang Kim, Thomas Bogenrieder, K. Park	2015	0
18	Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma Radiotherapy and Oncology ·Chia‐Chun Wang, Jason Chia‐Hsien Cheng, Chiao‐Ling Tsai, Jang‐Ming Lee, Pei‐Ming Huang, Chia‐Chi Lin, Chih‐Hung Hsu, Min‐Shu Hsieh, Yih‐Leong Chang, Feng‐Ming Hsu	2015	10
19	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy Urologic Oncology Seminars and Original Investigations ·Matthew D. Galsky, Erin Moshier, Xiuqing Wang, Chia‐Chi Lin, Noah M. Hahn, Thorsten Ecke, Guru Sonpavde, Gregory R. Pond, James Godbold, William Oh, Aristotle Bamias	2013	9
20	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies Cancer Chemotherapy and Pharmacology ·Chia‐Chi Lin, Muralidhar Beeram, Eric K. Rowinsky, Chris H. Takimoto, Chee M. Ng, Charles E. Geyer, Louis Denis, Johann S. de Bono, Desirée Hao, Anthony W. Tolcher, Sun Young Rha, Jacques Jolivet, Amita Patnaik	2009	2

About Chia‐Chi Lin

Chia‐Chi Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Endocrinology, Diabetes and Metabolism and Hematology, having authored 62 papers that have together received 3.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (11 papers), Colorectal Cancer Treatments and Studies (10 papers), Lung Cancer Research Studies (10 papers), Cancer therapeutics and mechanisms (6 papers), Bladder and Urothelial Cancer Treatments (5 papers), Multiple and Secondary Primary Cancers (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). The work is most often cited by research in Oncology (2.1k citations), Pulmonary and Respiratory Medicine (1.3k citations), Gastroenterology (193 citations), Immunology (627 citations) and Otorhinolaryngology (119 citations). Chia‐Chi Lin has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Ravit Geva, Hyun Cheol Chung, Shilpa Gupta, Joseph P. Eder, Kumudu Pathiraja, Barbara Burtness, Kei Muro, Yung‐Jue Bang, Talia Golan and Dung T. Le. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, European Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact